
One disease, one team, one #ALS community. No personal attacks, no smears, no obfuscating. DM with tips. #ALSfactcheck #endALS
Joined March 2021
- Tweets344
- Following158
- Followers77
- Likes224
Another trial is needed to confirm efficacy. No payday before proof.
Replying to @alsadvocacy @LLarry689
Do they have the data that show the magic characteristics of the responders?
If so, why not do another trial and get moving?
If not, then let's learn not to do trials like that ever again. 4/end
1
💯
Replying to @alsadvocacy @LLarry689
Nurown is a different situation imo since it didn't hit endpoints. I think they have to offer FDA more in order for the FDA to get to maybe. No doubt in my mind that it helps some people, but the trial Brainstorm designed didn't reflect efficacy. 2/
The evidence of absence on #NurOwn is deafening. Most #ALS researchers cower in labs hoping it will blow over, but it won’t until they stick out their necks & tell us how it is: is more evidence needed? The onus is on researchers to counter pharma TPs & preserve @US_FDA integrity
It’s not possible to prove a negative, but the evidence of absence is deafening: most ALS researchers & NurOwn PIs have been silent. ALS researchers are afraid to publicly come out against #NurOwn since ppl are running interference for pharma with the power to eviscerate careers.
3
Fact Check ALS retweeted
So many issues with this piece in @JAMAInternalMed from @US_FDA officials (Dunn, Stein, & Cavazzoni) attempting to justify their poor choice in approving #aducanumab - don't bother reading it unless you want your blood to boil. I'll summarize instead: jamanetwork.com/journals/jam… 1/
What @FinishALS said
1
Kewl.
You have no legitimacy to dictate how your own agency is investigated. You signed off 🖊
This Post is from an account that no longer exists. Learn more
.@BrainstormCell unblind now, show us the full data/ journal, apply for BLA if you think it works (or start another trial now on responders with EA, which you’ll be told to do regardless), but for gods sake stop letting #ALS patients die angry!
A thread on #NurOwn:
I have seen first hand a number of friends receive NurOwn in the EAP and through RTT.
Seen it slow or stop their progression.
As an ALS patient this makes me scream for access for all of us who are dying due to rampant systemic paternalism. /1
2
2
Fact Check ALS retweeted
The cynic in me fears the congressional hearing with the FDA on ALS and "other neurological diseases" could be taken over by discussions of "other neurological diseases" namely the Aduhelm approval. We need to make sure ALS is well represented both inside and outside the hearing.
So it’s not an #ALS hearing? Regardless, let’s not spoil this amazing opportunity by letting it go off the rails on #Aduhelm. There is real danger here in backfire & flexibilities being stripped away from FDA, like accelerated approval. We need more flexibility, not less.
Looking forward to holding a hearing later this month in the @EnergyCommerce Committee on the search for treatments for neurological diseases including ALS. More details soon!
We can’t let ourselves be co-opted into using pharma talking points about lowering standards & equate them to “flexibility”. PALS should have access to all promising treatments that are safe. Those treatments shouldn’t be approved without showing efficacy. NO PROOF, NO PAYDAY.
1
We don’t need lower standards, we need better science. To get a drug approval, pharma needs to put in the work and prove effectiveness. No proof, no payday.
And unblind your trial participants!!!!!!
Courage and conviction are words not often used with biopharma, but I’m going to:
@AmylyxPharma and @BrainstormCell today would be a great day to show courage and conviction in your therapies and in the ALS community. File the NDA and the BLA. Now. Make FDA decide. #ItsTime
True. @BrainstormCell’s current EAP is only 11-12 patients who likely responded in the trial. That won’t produce any data that FDA will use. They should use that money on another trial and provide access to ALL if they believe in Nurown.
Replying to @factcheckals @als_now @brainmatters10 @BrainstormCell @ShereeWLWT @MinoSean @stevens_nation @KathyCo74123384 @petenajarian
It’s probably the only way forward. I doubt the FDA will approve the drug based on an EA program that includes cherry picked participants. Another trial will likely be required, and if so it needs to have expanded access built on.
2
1
Take a read, important context.
We need another trial on #NurOwn to prove efficacy. Until then, @BrainstormCell needs to #unblindnurown & put money where it’s mouth is & pay for expanded access if they believe in NurOwn.
It’s incumbent on pharma to prove efficacy before payday.
We all want therapies for #mnd #als but not at the cost of ineffective ones making it to market. Without science and regulation, all is lost. My blog series on the real challenges of searching for treatments and why we must not shortcut.
onein300.com/the-devil-is-in…
2
5
Advancing the #ALS movement is not an American-only problem, it’s a human rights issue that doesn’t care about borders. Anyone can get it.
The new CEO must take on a leadership role @ALSMNDAlliance, which starts with joining it and advancing the cause worldwide.
#healthequity
There are some changes coming to the ALS movement but the urgency of this mission remains the same. Check out more here. iamals.org/updates/leadershi…
1
2
@iamalsorg is not a part of the international alliance, and what happens in America trickles down to the rest of the world. Their CEO must be at the table. The rest of the world deserves a community and home like IAA too, and I hope this will be part of the consideration.
3
2
Thank you, @D_Carnival for your service! Big shoes to fill.
As a member of the #ALS community, what “critical role” can we play in selecting your next CEO, @iamalsorg?
There are some changes coming to the ALS movement but the urgency of this mission remains the same. Check out more here. iamals.org/updates/leadershi…
1
1
Dear @BrainstormCell @AmylyxPharma,
I join the #ALS community calling for you to apply for @US_FDA approval of NurOwn and AMX.
I also urge you to immediately unblind trial participants & fully enroll confirmatory trials, before or after approval. It’s your duty to prove effect.









